Dr Reddy’s Knocked Back On Rituximab In US

Biosimilar Rival To Rituxan Receives Complete Response Letter From FDA

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Stop sign in front of US flag
Approval of Dr Reddy’s rituximab has been blocked in the US • Source: Shutterstock

More from Biosimilars

More from Products